COMMUNIQUÉS West-GlobeNewswire

Tempest Announces Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules
25/11/2025
$4.25 million upfront with up to an additional $4.1 million of potential aggregate gross proceeds upon the exercise in full of short-term unregistered warrants BRISBANE, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Tempest [...]
Flare Therapeutics to Participate in Piper Sandler 37th Annual Healthcare Conference
25/11/2025
CAMBRIDGE, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for oncology and other [...]
BrainsWay to Host Virtual Analyst & Investor Day to Discuss the Company’s Growth Strategy and Deep TMS™ Treatment December 1, 2025
25/11/2025
BURLINGTON, Mass. and JERUSALEM, Nov. 25, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation technologies, today [...]
BriaCell to Highlight Positive Phase 2 & Phase 3 Clinical Data at SABCS® 2025
25/11/2025
Three poster presentations at the San Antonio Breast Cancer Symposium (December 10, 2025) will highlight positive Phase 2 safety and efficacy signals and positive biomarker findings in both the Phase 2 and the pivotal [...]
BridgeBio to Participate in December Investor Conferences
25/11/2025
PALO ALTO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that [...]
Eisai Completes Rolling Submission to US FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status
25/11/2025
LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home injection from the start of therapy to help patients and care partners treat this progressive, [...]
Anavex Life Sciences Reports Fiscal 2025 Fourth Quarter Financial Results and Provides Business Update
25/11/2025
Company to host a webcast t oday at 8:30 a.m. Eastern Time NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company [...]
Clearmind Medicine Kicks-Off Patient Enrollment at Tel Aviv Sourasky Medical Center, Adding Another Site Activated in its in Phase I/IIa Alcohol Use Disorder Trial
25/11/2025
First patient recruited at leading Israeli site accelerating enrollment momentum across global study of CMND-100 Vancouver, Canada, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0 [...]
Kraig Biocraft Laboratories Launches Significant Hiring Initiative to Support Expanded Spider Silk Production Footprint in Southeast Asia
25/11/2025
ANN ARBOR, Mich., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), a world leader in spider silk technology*, announces the launch of a key hiring initiative [...]
Invivyd to Participate at the 8th Annual Evercore Healthcare Conference
25/11/2025
NEW HAVEN, Conn., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that management will participate in a fireside chat at the 8 th Annual Evercore Healthcare Conference on Tuesday, December [...]
Kymera Therapeutics Announces First Patient Dosed in BROADEN2 Phase 2b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader
25/11/2025
Data from the KT-621 BROADEN2 Phase 2b AD patient trial expected to be reported by mid-2027 KT-621 BREADTH Phase 2b trial in asthma on track to initiate in 1Q26 Completed dosing in KT-621 BroADen Phase 1b AD trial with [...]
C4 Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
25/11/2025
WATERTOWN, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced [...]
Zelluna ASA – Extraordinary General Meeting held on November 25, 2025
25/11/2025
Oslo, November 25, 2025: Zelluna ASA held its extraordinary general meeting today November 25, 2025. All the matters on the agenda were approved. The minutes from the meeting are enclosed and available at the company’s [...]
Adalyon Appoints Ulrik Zeuthen as CEO to Drive Next Phase of Growth in AI-driven Speech-based Biomarkers and Behavioural Analytics for Optimising Clinical Trials
25/11/2025
ESPOO, Finland, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Adalyon, a pioneering tech-bio company using its AI-powered speech biomarker platform to transform clinical drug development, today announced the appointment of Ulrik [...]
Macomics Announces Updated Data of the ENIGMAC Drug Discovery Platform and The Role of Macrophages in Fibrotic Disease
25/11/2025
EDINBURGH, United Kingdom and CAMBRIDGE, United Kingdom, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Macomics Ltd, a leader in macrophage drug discovery, announces that it has validated its ENIGMAC™ platform in macrophage [...]
Allegro and American Regent sign exclusive licensing deal for SynoglideTM, a novel osteoarthritis treatment in animal health, valued at up to $35 million
25/11/2025
Global license provides American Regent, a wholly owned subsidiary of Daiichi Sankyo, with rights to commercialize Synoglide™ in the veterinary market in most countries of the world. Allegro retains rights to human [...]
RAMSAY SANTE : Press release on November 25 2025
25/11/2025
PRESS RELEASE Paris, 25 th November 2025 Update on Ramsay Health Care Limited's review of its strategic options associated with its majority shareholding in Ramsay Générale de Santé On 27 February 2025, Ramsay Générale [...]
RAMSAY SANTE : communiqué de presse du 25 novembre 2025
25/11/2025
COMMUNIQUÉ DE PRESSE Paris, le 25 novembre 2025 Point sur la revue par Ramsay Health Care Limited de ses options stratégiques concernant sa participation majoritaire dans Ramsay Générale de Santé Le 27 février 2025, [...]
Novartis data underscore pioneering scientific innovation in Hematology and Oncology at ASH and SABCS
25/11/2025
Positive results from ianalumab pivotal Phase III trial in ITP patients previously treated with corticosteroids to be presented as late-breaker Scemblix data across clinical and real-world settings offer new evidence [...]

Pages